BRISTOL MYERS SQUIBB

Bristol Myers Squibb received FDA approval for Opdivo Qvantig, an injectable version of its cancer immunotherapy Opdivo, offering a quicker, more convenient dosing option. This approval covers all solid tumor indications previously approved for the IV version, aiming to maintain market share amidst upcoming competition.

The article content provided does not contain any substantive information or text to summarize.

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY) with a $62.00 price target. BMY shares closed at $57.68. Breen has a -5.2% average return and 50.00% success rate. Consensus is Hold, average target $60.69. BMY's market cap is $117B, P/E ratio -16.04. Insider sentiment is neutral.

FDA approves injectable Opdivo for cancer, enhancing immune system plasticity. Novartis faces revived kickback allegations for Gilenya. Kosovo reports first monkeypox case; BioNTech settles COVID vaccine royalty disputes with NIH and UPenn.

FDA approved Opdivo Qvantig, a subcutaneous treatment for solid tumors, offering faster administration and flexibility. Priced similarly to its IV version, it's based on CheckMate-67T trial results, showing comparable efficacy and safety. Available early 2025, with BMS ensuring patient access.

The FDA approved an injectable version of Bristol Myers Squibb’s cancer drug Opdivo, enhancing patient convenience and protecting sales. Priced similarly to the IV version, it treats solid tumors and uses Halozyme’s technology for quicker administration.

The article content is not provided or is empty, making it impossible to summarize.

Exicure, Inc. signed an MoU with GPCR Therapeutics to acquire GPCR USA, aiming for technology transfer and collaborative research on drug development pipelines, including a CXCR4 inhibitor in phase 2 trials. The deal involves $14 million in capital investments for acquisition and clinical trials.

The U.S. FDA approved Opdivo, Bristol Myers Squibb's injectable cancer immunotherapy, enhancing patient access and market position. This PD-1 inhibitor boosts the immune system's cancer-fighting ability, transitioning from IV to injectable for quicker administration. Despite nearing a patent cliff, the move aims to sustain sales and market dominance, with BMY shares rising significantly.